Jafron Biomedical convertible bond nears conversion price adjustment trigger

Jafron Biomedical has announced that its convertible bond, "Jafron Convert," with a current conversion price of RMB 38.65 per share, is nearing the conditions for a potential downward adjustment. As of November 17, 2025, the company's stock price had traded below 85% of the current conversion price for ten trading days since November 4, 2025.

According to the bond's prospectus, if the company's stock closing price falls below 85% of the current conversion price for at least 15 trading days within any continuous 30-trading-day period, the board of directors is authorized to propose a downward revision. If triggered, the company will initiate the necessary approval procedures and information disclosure.

The latest effective conversion price for "Jafron Convert" was set at RMB 38.65 per share following a rights distribution adjustment on May 26, 2025. Investors are advised to monitor developments closely as any adjustment would follow board and shareholder approval, impacting the bond's conversion terms.